ADMA Biologics, Inc.
ADMA
$17.02
$0.110.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 398.49% | 186.35% | 92.36% | 57.15% | 67.54% |
| Total Depreciation and Amortization | 0.51% | 5.34% | 11.23% | 17.01% | 21.89% |
| Total Amortization of Deferred Charges | -39.78% | -27.99% | 2.73% | 8.38% | -0.89% |
| Total Other Non-Cash Items | 275.75% | 290.83% | 304.99% | 138.92% | -30.07% |
| Change in Net Operating Assets | -108.73% | 59.32% | -14.27% | 44.63% | 64.28% |
| Cash from Operations | 631.97% | 276.15% | 144.18% | 114.79% | 81.10% |
| Capital Expenditure | 8.96% | 35.98% | 60.25% | 65.70% | 47.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1.23% | 30.71% | 58.52% | 64.19% | 47.09% |
| Total Debt Issued | -- | -- | -- | -11.04% | -100.00% |
| Total Debt Repaid | -763,402.02% | -467,702.36% | -428,524.32% | -58.54% | 99.98% |
| Issuance of Common Stock | -89.29% | -96.95% | -96.71% | -98.30% | 22.46% |
| Repurchase of Common Stock | -48.57% | -10.52% | 5.72% | 51.21% | -277.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15,076,900.00% | -3,625.48% | -3,625.48% | -215.21% | 100.00% |
| Cash from Financing | -205.61% | -165.68% | -165.30% | -135.82% | -37.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.03% | 154.81% | -7,838.56% | -199.26% | 7,823.11% |
